Science Pool

Date: 30th June - 2nd July 2022

Location: Sapporo Convention Center

Attendees: Masaaki Yatsu & Tim Potter 

Read more about 49th Annual Meeting of the JSOT

Learn more about fighting tuberculosis by targeting the essential enzyme PptT.

Together with collaborators at Weill Cornell Medical College, Texas Agricultural and Mechanical University (TAMU), and  University of North Carolina (UNC), we identified the amidinourea compound AU8918, through a phenotypic screen, as an interesting anti-TB compound. We went on to identify its target within Mycobacterium tuberculosis, as phosphopantetheinyl transferase (PptT) - an essential enzyme involved in synthesis of cellular lipids and virulence factors.

This paper describes:

• Next steps taken in further pursuit of this novel anti-TB series
• An expanded collaboration within the TB Drug Accelerator consortium
• Latest structure guided SAR exploration around AU8918 for more potent and safest Lead-like analogs

GET THE PAPER

Learn more about our abuse liability services including:

• Compound characterization
• Pharmacological assessment
• Preclinical Behavioral studies
• Integration within a multidisciplinary full-scope clinical-enabling program with chemistry,
  pharmacology, DMPK, safety assessment, regulatory and clinical support, all driven by our drug
  development experts

DOWNLOAD

Learn more about INDiGO and Evotec's integrated preclinical development capabilities to de-risk and accelerate IND-enabling programs:

• Typically, drug candidates can be advanced from candidate selection to IND-submission in 48–52 weeks
• Our experienced team not only executes R&D projects, but also proactively contributes to your scientific strategy
• Clients can either opt for the full INDiGO platform or selected preclinical development and CMC components

DOWNLOAD

Learn more about our pathology services including:

• GLP certification with highest quality standards and an impeccable regulatory inspection history
• Unparalleled flexibility with all capabilities in-house and under one roof
• ACVP/DECVP, MRCPATH, DECLAM, DECVCP qualified pathologists/clinical pathologists

DOWNLOAD

Learn more about our safety assessment services including:

• Toxicology core capabilities
• Safety pharmacology (GLP) studies
• Genetic toxicology (GLP) studies
• Additional capabilities such as bioanalytical method development and GLP validation, DMPK, immunoassays, immunogenicity testing, immunotoxicology assays

DOWNLOAD

Date: 21 - 25 March 2022

Location: Renaissance Seattle Hotel, Seattle, WA, United States | Hybrid Event

Attending: Kara Carter, Antoine Alam, Jon Gunther, Randal Ketchem, and Cristina Loomis

Evotec will be sponsoring ICAR 2022 and showcasing its research along with our Just - Evotec Biologics colleagues. 

Presentation

AI-Derived Antibody Discovery - Humanoids for Global Good

Randal Ketchem, SVP Biotherapeutic Discovery and Molecular Design at Just – Evotec Biologics
Thursday, March 24 | 2:45 pm - 5:45 pm

Presentation

A Bifunctional Immune Modulator Exhibits Potent Antiviral Activity in HBV Infection Models

Antoine Alam, Head of Virology at Evotec
Friday, March 23 | 12:15 pm - 1:00 pm

Poster

AI-Derived Antibodies Are Novel, Diverse and Pharmacologically Active Against Multiple Sars-Cov-2 Strains

Kara Carter will be chairing four sessions:

Monday, March 21 | 4:30 pm - 5:30 pm
Gertrude Elion Memorial Award Lecture

Tuesday, March 22 | 2:00 pm - 2:45 pm
William Prusoff Memorial Award Lecture

Wednesday, March 23 |  8:30 am - 9:15 am
Antonín Holý Memorial Award Lecture

Thursday, March 24 | 2:45 pm - 5:45 pm
Coronaviruses

If you wish to meet with us in Seattle, get in touch via the form below, we will be happy to arrange a meeting.

Watch our webinar and learn about exciting new developments in toxicology prediction and how transcriptomics is transforming DILI prediction.

Drug-induced toxicity remains a major source of attrition in preclinical and clinical. In particular, drug-induced liver injury (DILI) can be difficult to predict as it often has poor translation from animals to humans and so issues are only picked up during clinical development or post-market approval. In fact, 18% of drug withdrawals from the market are caused by DILI. These statistics have led to a push within the industry to bring testing earlier using more human relevant cell-based models. However, challenges still exist and more accurate techniques are required to improve the predictive capabilities.

About the Webinar

The webinar covers our ground-breaking work in the field of transcriptomics. Cyprotex and Evotec have jointly created a fully integrated in vitro prediction platform using 2D and 3D cell-based models combined with high throughput RNA-seq and sophisticated machine learning and artificial intelligence techniques. The company is building the largest transcriptomic database in the world. This will be used to predict the likelihood of DILI risk, mechanistic information and similarity profiles to existing compounds. Our initial data shows an impressive accuracy of DILI prediction of 82% compared with 70% for a seven read-out HCS-based DILI platform.

About the Speaker

Paul Walker PhD VP, Head of Tox and Innovation Efficiency | Cyprotex Dr Paul Walker is the Head of Toxicology at Cyprotex where he is responsible for the development of strategy, innovation and management of client work performed within the Toxicology Group. Paul obtained his Ph.D. from King’s College London in Molecular Toxicology being awarded the Tadion-Rideal prize for molecular sciences (2004). Paul further developed his understanding of molecular biology and toxicology during his post-doctoral years at the University of Manchester with a keen interest in the application of high content imaging and 3D models within this field. Paul joined Cyprotex in 2010 with his research interests focused on the role of drug metabolism in drug toxicity and in vitro assays to predict toxicity in early drug discovery.

Watch the webinar to learn more!

[hs-form id="ca659dbc-caf4-4fd4-acee-887701b948a5" show="hide on login" url="https://news.evotecsciencepool.com/hubfs/Sciencepool/Videos%20and%20Webinars/Cyprotex%20webinars%20and%20videos/transcriptomics-the-future-of-toxicology-prediction-webinar.mp4"]

Watch the webinar to learn more about exciting new developments in predictive toxicology!

About the Webinar

In this webinar, Dr Alicia Rosell-Hidalgo will present how high content screening (HCS) and high throughput RNA-seq techniques in conjunction with 3D liver models can be used to improve toxicology prediction and gain an in-depth mechanistic understanding of drug-induced toxicity. The presentation will focus predominantly on drug induced liver injury (DILI) with relevant case studies to demonstrate utility in safety profiling.

About the Speaker

Alicia Rosell-Hidalgo PhD Associate Principal Scientist | Cyprotex Dr Alicia Rosell-Hidalgo is an Associate Principal Scientist in Toxicology at Cyprotex Discovery Ltd, a subsidiary of Evotec SE. She leads the in vitro research and development carried out in the UK site for the “Panomics” project, aimed at improving predictive toxicology through 2D and 3D cell-based models combined with high throughput RNA-seq and machine learning/artificial intelligence techniques. Alicia has a bachelor’s of science in Biology and master’s degree in Biochemistry at the University Complutense of Madrid. During her undergraduate years, she gained laboratory experience through collaborations with the Spanish National Research Council (CSIC) and the University of Brighton. In 2020, she was awarded a Ph.D. by the University of Sussex, where she researched drug-induced mitochondrial dysfunction.

Watch the webinar to learn more!

[hs-form id="4da29068-493a-42b5-a991-0d693e64de89" show="hide on login" url="https://news.evotecsciencepool.com/hubfs/Sciencepool/Videos%20and%20Webinars/Cyprotex%20webinars%20and%20videos/transcriptomics-in-3d-cellular-models-webinar.mp4"]

Learn about exciting new developments in pharmacokinetic prediction, and how to transform your use of ADME data.

About the Webinar

Whilst early in vitro screening for absorption, distribution metabolism and elimination (ADME) properties has significantly transformed early drug screening in many companies, the corresponding ability to quickly, and reliably, predict pharmacokinetics (PK) from these data has lagged behind. In vivo human prediction still largely relies on scaling from animal in vivo PK data, precluding its use for mass PK screening in early discovery.

In this webinar our expert, Simon Thomas, outlines Cyprotex's most recent work in the prediction of human PK from early ADME data. Combining ADME data with physicochemical and structural information within a novel physiologically based pharmacokinetic (PBPK) model, we have developed a service that returns a comprehensive array of reliable PK data and metrics: summary PK parameters and plasma concentrations are predicted for oral, intravenous bolus and intravenous infusion administration, whether single- or repeat-dose regimes. Generation of these predictions greatly enhances the value of the ADME data, and facilitates multiple options for directing compound progression: use of the predicted PK parameters enables compounds with desirable properties to be identified, whilst reliable plasma concentration prediction enables the implementation of pharmacokinetic/pharmacodynamic (PK/PD) modelling for early assessment of in vivo potential. High throughput and rapid turnaround maximally facilitate the make-test-analyse process.

About the Speaker

Simon Thomas PhD Head of Modelling and Simulation | Cyprotex Dr Simon Thomas is the Head of Modelling and Simulation at Cyprotex where he is responsible for the development of mathematical models for predicting ADME properties, pharmacokinetics, toxicity and clinical efficacy. Simon studied chemistry at the University of Oxford, as a final year student writing his first computer models, on the emission of electrons via the photoelectric effect. He obtained his Ph.D. and carried out post-doctoral work in the nascent field of systems biology at Oxford Brookes University, modelling the regulation of biochemical pathways in plants and animals, particularly with respect to pathways of energy metabolism. He joined Cyprotex in 1999, initially leading the company’s modelling efforts in PK prediction, over time extending the company’s capabilities into prediction of toxicity and pharmacological activity.

Watch the webinar to learn more!

[hs-form id="65ebef6f-b35d-4dff-a609-c8f1b77e39c4" show="hide on login" url="https://news.evotecsciencepool.com/hubfs/Sciencepool/Videos%20and%20Webinars/Cyprotex%20webinars%20and%20videos/pk-prediction-in-early-drug-discovery-webinar-nov2021.mp4"]